Pharmaceutical Policy

Improving the Quality, Safety and Efficiency of Medication Use

While prescription drugs are used by 80% of Americans, the improper, often unsafe use of medications leads to billions of dollars of avoidable healthcare costs. The goal of the CP3 research program is to improve patient and prescriber decision-making, and inform the regulation and coverage of pharmaceuticals. More >


Fellows' Research Seminar

Join us on 4/23, when you can meet CP3's postdoctoral fellows and learn about their current and future research.

Focus on Deprescribing

Recent papers from affiliated faculty show importance of training for deprescribing work and identifying it in clinical practice.

Past Seminar

On 12/4, we welcomed Stacie Dusetzina, PhD, from Vanderbilt University. This event was co-sponsored by Pitt Public Health, Department of Health Policy and Management.

340B Debate Perspective

In a perspective piece in the New England Journal of Medicine, CP3 Director Walid Gellad and HPI Director Everette James describe the controversy surrounding the 340B Drug Pricing Program.Read more.

Prescribing habits following overdose

In a recent article in JAMA, researchers compared prescription opioid use and medication-assisted treatment rates before and after an overdose. 

Accelerated Drug Approval

In a recent perspective piece in NEJM, Dr. Gellad discusses the accelerated approval process in the era of expensive drugs. Read more.